You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

341 Results
Guidelines and Advice
Mar 2024
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-24
Version: 3
Jan 2024
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Guidelines and Advice
Status: Current
ID: ES PET 16
Version: 2
Apr 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
High Cost Therapy Funding Program
    Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Advanced Malignant Pleural Mesothelioma (MPM)
Oct 2024
Regimen
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Ipilimumab - Previously Untreated Advanced Unresectable Melanoma
New Drug Funding Program
    Ipilimumab - Previously Treated Advanced Unresectable Melanoma
Aug 2024

Pages